Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 4/2009

01-04-2009 | Original Article

Mapping the prescriptiome to fractures in men—a national analysis of prescription history and fracture risk

Authors: B. Abrahamsen, K. Brixen

Published in: Osteoporosis International | Issue 4/2009

Login to get access

Abstract

Summary

A nationwide case-control study was performed in 62,865 men aged 50+ using fracture data from the national hospital discharge register to screen all redeemed prescriptions in the past 5 years for significant mapping to fracture risk, employing measures to control for false discovery rate.

Introduction

Osteoporosis in men is frequently related to alcohol abuse, hypogonadism, hypercalciuria, or the use of glucocorticoids. Very limited information is available on the impact of other medications on fracture risk in men.

Methods

We conducted a nationwide population-based case-control study collecting fracture data from the Danish National Hospital Discharge Register and prescriptions from the National Prescriptions Database (1995–2000). We included men aged 50+ years, with hospital-treated fractures in the year 2000 (n = 15,716), and age- and sex-matched controls (n = 47,149).

Results

We identified 3.2 million redemptions of prescriptions for 1,073 different drugs. The analysis confirmed associations between fracture risk and use of sedatives, anti-epileptics, anti-psychotics, anxiolytics, SSRI, opioids and other analgesics, loop diuretics, and glucorticoids. New associations were also found. We observed an odds ratio (OR [95% CI] for any fracture) for fracture in users of dopaminergic agents (1.6 [1.3–1.9]) and iron compounds (1.2 [1.1–1.5]). The largest impact on fracture risk at population level was exerted by loop diuretics and analgesics.

Conclusions

An array of drugs is associated with fracture risk in men. The “prescriptiome” analysis can be used as a surveillance tool for drug-induced osteoporosis and in the planning of preventive measures.
Literature
1.
Johnell O, Kanis J (2005) Epidemiology of osteoporotic fractures. Osteoporos Int 16(Suppl 2):S3–S7PubMedCrossRef
2.
3.
4.
Ebeling PR, Thomas DM, Erbas B, Hopper JL, Szer J, Grigg AP (1999) Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. J Bone Miner Res 14:342–350PubMedCrossRef
5.
Bardin T, Lequesne M (1989) The osteoporosis of heparinotherapy and systemic mastocytosis. Clin Rheumatol 8(Suppl 2):119–123PubMedCrossRef
6.
Ahmed LA, Schirmer H, Berntsen GK, Fonnebo V, Joakimsen RM (2006) Self-reported diseases and the risk of non-vertebral fractures: the Tromso study. Osteoporos Int 17:46–53PubMedCrossRef
7.
Vestergaard P, Mosekilde L (2002) Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid 12:411–419PubMedCrossRef
8.
Vestergaard P, Rejnmark L, Mosekilde L (2004) Fracture risk associated with use of antiepileptic drugs. Epilepsia 45:1330–1337PubMedCrossRef
9.
Takkouche B, Montes-Martinez A, Gill SS, Etminan M (2007) Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf 30:171–184PubMedCrossRef
10.
Meyer JM, Lehman D (2006) Bone mineral density in male schizophrenia patients: a review. Ann Clin Psychiatry 18:43–48PubMedCrossRef
11.
Lonning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G (2005) Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23:5126–5137PubMedCrossRef
12.
Abrahamsen B, Frost MM, Walther S, Brixen K (2007) Fracture risk in patients with prostate cancer. A nationwide case-control study. Br J Urol 100(4):749–754
13.
Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349–3354PubMedCrossRef
14.
Paton NI, Macallan DC, Griffin GE, Pazianas M (1997) Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int 61:30–32PubMedCrossRef
15.
Hakonarson H, Grant SF, Bradfield JP, Marchand L, Kim CE, Glessner JT, Grabs R, Casalunovo T, Taback SP, Frackelton EC, Lawson ML, Robinson LJ, Skraban R, Lu Y, Chiavacci RM, Stanley CA, Kirsch SE, Rappaport EF, Orange JS, Monos DS, Devoto M, Qu HQ, Polychronakos C (2007) A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 448(7153):591–594PubMedCrossRef
16.
Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259PubMed
17.
Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA (2006) The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int 17:1404–1409PubMedCrossRef
18.
van Staa TP, Leufkens HG, Cooper C (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787PubMedCrossRef
19.
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383PubMedCrossRef
20.
Schneeweiss S, Wang PS, Avorn J, Glynn RJ (2003) Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res 38:1103–1120PubMedCrossRef
21.
Hochberg Y, Benjamini Y (1990) More powerful procedures for multiple significance testing. Stat Med 9:811–818PubMedCrossRef
22.
Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 79:76–783PubMedCrossRef
23.
Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J (2001) Zolpidem use and hip fractures in older people. J Am Geriatr Soc 49:1685–1690PubMedCrossRef
24.
Vestergaard P, Rejnmark L, Mosekilde L (2006) Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 17:807–816PubMedCrossRef
25.
Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ III (1987) Psychotropic drug use and the risk of hip fracture. N Engl J Med 316:363–369PubMed
26.
Schneeweiss S, Wang PS (2004) Association between SSRI use and hip fractures and the effect of residual confounding bias in claims database studies. J Clin Psychopharmacol 24:632–638PubMedCrossRef
27.
Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N (1998) Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 351:1303–1307PubMedCrossRef
28.
Shorr RI, Griffin MR, Daugherty JR, Ray WA (1992) Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene. J Gerontol 47:M111–M115PubMed
29.
Vestergaard P, Rejnmark L, Mosekilde L (2006) Fracture risk associated with the use of morphine and opiates. J Intern Med 260:76–87PubMedCrossRef
30.
Vestergaard P, Rejnmark L, Mosekilde L (2006) Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis. Calcif Tissue Int 79:84–94PubMedCrossRef
31.
Fink HA, Kuskowski MA, Orwoll ES, Cauley JA, Ensrud KE (2005) Association between Parkinson’s disease and low bone density and falls in older men: the osteoporotic fractures in men study. J Am Geriatr Soc 53:1559–1564PubMedCrossRef
32.
33.
Rejnmark L, Vestergaard P, Mosekilde L (2006) Fracture risk in patients treated with loop diuretics. J Intern Med 259:117–124PubMedCrossRef
34.
Lim LS, Fink HA, Kuskowski MA, Cauley JA, Ensrud KE (2005) Diuretic use and bone mineral density in older USA men: the osteoporotic fractures in men (MrOS) study. Age Ageing 34:504–507PubMedCrossRef
35.
Sennerby U, Farahmand B, Ahlbom A, Ljunghall S, Michaelsson K (2007) Cardiovascular diseases and future risk of hip fracture in women. Osteoporos Int 18(10):1355–1362PubMedCrossRef
36.
Richy F, Bousquet J, Ehrlich GE, Meunier PJ, Israel E, Morii H, Devogelaer JP, Peel N, Haim M, Bruyere O, Reginster JY (2003) Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int 14:179–190PubMed
37.
de Vries F, Pouwels S, Lammers JW, Leufkens HG, Bracke M, Cooper C, van Staa TP (2007) Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med 261:170–177PubMed
38.
Bonnet N, Laroche N, Vico L, Dolleans E, Benhamou CL, Courteix D (2006) Dose effects of propranolol on cancellous and cortical bone in ovariectomized adult rats. J Pharmacol Exp Ther 318:1118–1127PubMedCrossRef
39.
Bonnet N, Gadois C, McCloskey E, Lemineur G, Lespessailles E, Courteix D, Benhamou CL (2007) Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone 40:1209–1216PubMedCrossRef
40.
Rejnmark L, Vestergaard P, Mosekilde L (2006) Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 24:581–589PubMedCrossRef
41.
Meisinger C, Heier M, Lang O, Doring A (2007) Beta-blocker use and risk of fractures in men and women from the general population: the MONICA/KORA Augsburg cohort study. Osteoporos Int 18:1189–1195PubMedCrossRef
42.
Rejnmark L, Vestergaard P, Kassem M, Christoffersen BR, Kolthoff N, Brixen K, Mosekilde L (2004) Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 75:365–372PubMedCrossRef
43.
de Vries F, Souverein PC, Cooper C, Leufkens HGM, van Staa TP (2007) Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and the Netherlands. Calcif Tissue Int 80:69–75PubMedCrossRef
44.
Ferencz V, Meszaros S, Csupor E, Toth E, Bors K, Falus A, Horvath C (2006) Increased bone fracture prevalence in postmenopausal women suffering from pollen-allergy. Osteoporos Int 17:484–491PubMedCrossRef
45.
Ross RW, Small EJ (2002) Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 167:1952–1956PubMedCrossRef
46.
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2006) Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst 98:839–845PubMedCrossRef
47.
Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J (2007) Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69:500–504PubMedCrossRef
48.
Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J (2006) Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 175:136–139PubMedCrossRef
49.
Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA (2005) Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 16:707–711PubMedCrossRef
50.
Vestergaard P, Rejnmark L, Mosekilde L (2005) Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48:1292–1299PubMedCrossRef
51.
Clark MK, Sowers MF, Dekordi F, Nichols S (2003) Bone mineral density and fractures among alcohol-dependent women in treatment and in recovery. Osteoporos Int 14:396–403PubMedCrossRef
52.
Dhonukshe-Rutten RA, Pluijm SM, de Groot LC, Lips P, Smit JH, van Staveren WA (2005) Homocysteine and vitamin B12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. J Bone Miner Res 20:921–929PubMedCrossRef
53.
Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K (2005) Effect of folate and mecobalamin on Hip fractures in patients with stroke—a randomized controlled trial. JAMA 293:1082–1088PubMedCrossRef
54.
55.
The European Agency for the Evaluation of Medicinal Products. Points to consider on multiplicity issues in clinical trials, EMEA CPMP/EWP/908/99, London 2002). 2008; EMEA CPMP/EWP/908/99
56.
de Vries F, de Vries C, Cooper C, Leufkens B, van Staa TP (2006) Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int J of Epid 35:1301–1308CrossRef
57.
Rejnmark L, Vestergaard P, Mosekilde L (2007) Fracture risk in users of oral anticoagulants: a nationwide case-control study. Int J Cardiol 118:338–344PubMedCrossRef
58.
Steinbuch M, Youket TE, Cohen S (2004) Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 15:323–328PubMedCrossRef
59.
van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48:3224–3229PubMedCrossRef
60.
Vestergaard P, Olsen ML, Paaske JS, Rejnmark L, Sorensen HT, Mosekilde L (2003) Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark. J Intern Med 254:486–493PubMedCrossRef
61.
van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54:3104–3112PubMedCrossRef
62.
Grisso JA, Kelsey JL, O’Brien LA, Miles CG, Sidney S, Maislin G, LaPann K, Moritz D, Peters B (1997) Risk factors for hip fracture in men. Hip Fracture Study Group. Am J Epidemiol 145:786–793PubMed
63.
Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164PubMedCrossRef
64.
Souverein PC, Webb DJ, Weil JG, van Staa TP, Egberts AC (2006) Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 66:1318–1324PubMedCrossRef
65.
Vestergaard P (2005) Epilepsy, osteoporosis and fracture risk—a meta-analysis. Acta Neurol Scand 112:277–286PubMedCrossRef
66.
Vestergaard P, Tigaran S, Rejnmark L, Tigaran C, Dam M, Mosekilde L (1999) Fracture risk is increased in epilepsy. Acta Neurol Scand 99:269–275PubMedCrossRef
67.
Teo JS, Briffa NK, Devine A, Dhaliwal SS, Prince RL (2006) Do sleep problems or urinary incontinence predict falls in elderly women? Aust J Physiother 52:19–24PubMed
68.
Avidan AY, Fries BE, James ML, Szafara KL, Wright GT, Chervin RD (2005) Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes. J Am Geriatr Soc 53:955–962PubMedCrossRef
69.
Ray WA, Griffin MR, Malcolm E (1991) Cyclic antidepressants and the risk of hip fracture. Arch Intern Med 151:754–756PubMedCrossRef
70.
Hubbard R, Farrington P, Smith C, Smeeth L, Tattersfield A (2003) Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 158:77–84PubMedCrossRef
71.
Whooley MA, Kip KE, Cauley JA, Ensrud KE, Nevitt MC, Browner WS (1999) Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 159:484–490PubMedCrossRef
Metadata
Title
Mapping the prescriptiome to fractures in men—a national analysis of prescription history and fracture risk
Authors
B. Abrahamsen
K. Brixen
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 4/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-008-0711-2

Other articles of this Issue 4/2009

Osteoporosis International 4/2009 Go to the issue

Original Article

Heritability of impaired balance: a nationwide cohort study in twins

Original Article

The Osteoporosis Self-Assessment Tool versus alternative tests for selecting postmenopausal women for bone mineral density assessment: a comparative systematic review of accuracy

Original Article

Milk, rather than other foods, is associated with vertebral bone mass and circulating IGF-1 in female adolescents

Original Article

Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response

Review

Phytotherapy versus hormonal therapy for postmenopausal bone loss: a meta-analysis

Original Article

Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebra